Literature DB >> 24025972

HER-2/neu mediates oncogenic transformation via altered CREB expression and function.

André Steven1, Sandra Leisz, Chiara Massa, Manuela Iezzi, Rossano Lattanzio, Alessia Lamolinara, Jürgen Bukur, Anja Müller, Bernhard Hiebl, Hans-Jürgen Holzhausen, Barbara Seliger.   

Abstract

UNLABELLED: The cyclic (c)AMP responsive element binding protein (CREB) plays a key role in many cellular processes, including differentiation, proliferation, and signal transduction. Furthermore, CREB overexpression was found in tumors of distinct origin and evidence suggests an association with tumorigenicity. To establish a mechanistic link between HER-2/neu-mediated transformation and CREB protein expression and function, in vitro models of HER-2/neu-overexpressing and HER-2/neu-negative/silenced counterparts as well as human mammary carcinoma lesions with defined HER-2/neu status were used. HER-2/neu overexpression resulted in the induction and activation of CREB protein in vitro and in vivo, whereas short hairpin RNA (shRNA)-mediated inhibition of HER-2/neu correlated with downregulated CREB activity. CREB activation in HER-2/neu-transformed cells enhanced distinct signal transduction pathways, whereas their inhibition negatively interfered with CREB expression and/or activation. CREB downregulation in HER-2/neu-transformed cells by shRNA and by the inhibitors KG-501 and lapatinib caused morphologic changes, reduced cell proliferation with G0-G1 cell-cycle arrest, which was rescued by CREB expression. This was accompanied by reduced cell migration, wound healing, an increased fibronectin adherence, invasion, and matrix metalloproteinase expression. In vivo shCREB-HER-2/neu(+) cells, but not control cells, exerted a significantly decreased tumorgenicity that was associated with decreased proliferative capacity, enhanced apoptosis, and increased frequency of T lymphocytes in peripheral blood mononuclear cells. Thus, CREB plays an important role in the HER-2/neu-mediated transformation by altering in vitro and in vivo growth characteristics. IMPLICATIONS: These data suggest that CREB affects tumor immunogenicity and is a potential target for cancer therapy. ©2013 AACR.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24025972     DOI: 10.1158/1541-7786.MCR-13-0125

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  17 in total

1.  Modulation of MHC class I surface expression in B16F10 melanoma cells by methylseleninic acid.

Authors:  Claudia Lennicke; Jette Rahn; Jürgen Bukur; Falko Hochgräfe; Ludger A Wessjohann; Rudolf Lichtenfels; Barbara Seliger
Journal:  Oncoimmunology       Date:  2016-12-21       Impact factor: 8.110

Review 2.  cAMP Signaling in Cancer: A PKA-CREB and EPAC-Centric Approach.

Authors:  Muhammad Bilal Ahmed; Abdullah A A Alghamdi; Salman Ul Islam; Joon-Seok Lee; Young-Sup Lee
Journal:  Cells       Date:  2022-06-24       Impact factor: 7.666

3.  DCC is expressed in a CD166-positive subpopulation of chondrocytes in human osteoarthritic cartilage and modulates CRE activity.

Authors:  Anja-Katrin Bosserhoff; Simone Hofmeister; Anke Ruedel; Thomas Schubert
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

4.  N-Acetylglucosaminyltransferase III (GnT-III) but not N-Acetylgalactosaminyltransferase-6 and 8 are Differentially Expressed in Invasive and In Situ Ductal Carcinoma of the Breast.

Authors:  Antônio Felix da Silva Filho; Gabriela Souto Vieira-de-Mello; Petra Barros Dos Santos; Moacyr Jesus Barreto de Melo Rêgo; Alfredo Ribeiro-Silva; Eduardo Isidoro Carneiro Beltrão
Journal:  Pathol Oncol Res       Date:  2019-01-28       Impact factor: 3.201

5.  Biglycan-mediated upregulation of MHC class I expression in HER-2/neu-transformed cells.

Authors:  Karthikeyan Subbarayan; Sandra Leisz; Claudia Wickenhauser; Daniel Bethmann; Chiara Massa; André Steven; Barbara Seliger
Journal:  Oncoimmunology       Date:  2018-01-16       Impact factor: 8.110

6.  Caveolin-1 temporal modulation enhances antibody drug efficacy in heterogeneous gastric cancer.

Authors:  Patrícia M R Pereira; Komal Mandleywala; Sébastien Monette; Melissa Lumish; Kathryn M Tully; Sandeep Surendra Panikar; Mike Cornejo; Audrey Mauguen; Ashwin Ragupathi; Nai C Keltee; Marissa Mattar; Yelena Y Janjigian; Jason S Lewis
Journal:  Nat Commun       Date:  2022-05-09       Impact factor: 17.694

Review 7.  Control of CREB expression in tumors: from molecular mechanisms and signal transduction pathways to therapeutic target.

Authors:  André Steven; Barbara Seliger
Journal:  Oncotarget       Date:  2016-06-07

8.  Hypoxia-mediated alterations and their role in the HER-2/neuregulated CREB status and localization.

Authors:  André Steven; Sandra Leisz; Katharina Sychra; Bernhard Hiebl; Claudia Wickenhauser; Dimitrios Mougiakakos; Rolf Kiessling; Carsten Denkert; Barbara Seliger
Journal:  Oncotarget       Date:  2016-08-09

9.  Synergistic effects of IL-4 and TNFα on the induction of B7-H1 in renal cell carcinoma cells inhibiting allogeneic T cell proliferation.

Authors:  Dagmar Quandt; Simon Jasinski-Bergner; Ulrike Müller; Bianca Schulze; Barbara Seliger
Journal:  J Transl Med       Date:  2014-05-30       Impact factor: 5.531

10.  Loss of epithelium-specific GPx2 results in aberrant cell fate decisions during intestinal differentiation.

Authors:  Claudia Lennicke; Jette Rahn; Claudia Wickenhauser; Rudolf Lichtenfels; Andreas S Müller; Ludger A Wessjohann; Anna P Kipp; Barbara Seliger
Journal:  Oncotarget       Date:  2017-11-23
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.